Drug Trial Radar · NCT05816642
Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma
Last checked: Nov 20, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
500
Planned (sponsor's estimate)
Start
Aug 1, 2022
Primary completion
Dec 31, 2023
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- RenJi HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ruijin Hospital; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine; West China Hospital; Xiangya Hospital of Central South University; Fudan University; Second Affiliated Hospital, Zhejiang University, School of Medicine; Second Affiliated Hospital of Nantong University; Peking University First Hospital; Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University; Shanghai Jiao Tong University Affiliated Sixth People's Hospital; Zhejiang University; First Affiliated Hospital of Wenzhou Medical University; Sir Run Run Shaw Hospital; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School; The General Hospital of Eastern Theater Command; The First Affiliated Hospital with Nanjing Medical University; The First Affiliated Hospital of University of Science and Technology of China; The Second Hospital of Anhui Medical University; Tongji Hospital; The First Affiliated Hospital of Zhengzhou University; Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital; The First Affiliated Hospital of Shanxi Medical University; Shanxi Province Cancer Hospital; Changzhi Medical College; First Affiliated Hospital Xi'an Jiaotong University; Second Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Air Force Medical University; Tang-Du Hospital; Quanzhou First Hospital; Third Affiliated Hospital, Sun Yat-Sen University
- First posted
- Apr 18, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Screening
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Next-Generation Sequencing and whole transcriptome RNA sequencing were used to detect genomic variation and expression in tissues or blood, respectively. The treatment outcome of single targeted therapy or combined with immunotherapy was observed and followed up. Through this study, we intend to achieve RNA molecular classification of Chinese mRCC patients and to evaluate the correlation between ctDNA level, RNA molecular classification and treatment outcome, provide reference for metastatic RCC precise diagnosis and treatment.
Conditions
- Metastatic Renal Cell Carcinoma
Interventions
sunitinib or pazopanibDrug
Single targeted therapy
PD-1 inhibitor combined with axitinibDrug
targeted therapy combined with immunotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- progression-free survivalTime frame: From drug taken until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.